LEMTRADA Drug Profile

Summary for Tradename: LEMTRADA

High Confidence Patents:	8
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for LEMTRADA

Recent Clinical Trials for LEMTRADA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	Phase 1
M.D. Anderson Cancer Center	Phase 1
National Cancer Institute (NCI)	Phase 1

See all LEMTRADA clinical trials

Pharmacology for LEMTRADA

Mechanism of Action	CD52-directed Antibody Interactions
Established Pharmacologic Class	CD52-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LEMTRADA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LEMTRADA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	5,545,403	2013-11-23	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	5,545,405	2014-11-03	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	5,654,403	2014-04-28	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	5,846,534	2014-04-29	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	6,290,961	2020-01-24	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	6,569,430	2015-03-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LEMTRADA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,016,338	2036-12-20	Patent claims search
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,022,427	2036-01-18	Patent claims search
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,022,451	2035-05-11	Patent claims search
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,047,163	2034-02-07	Patent claims search
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,053,498	2035-11-20	Patent claims search
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	10,059,765	2035-07-01	Patent claims search

International Patents for LEMTRADA

Country	Patent Number	Estimated Expiration
Denmark	126292
Japan	3238154
Japan	2012167115
Germany	69428813
Hong Kong	1070831
United Kingdom	8804464

Supplementary Protection Certificates for LEMTRADA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C 2016 020	Romania		PRODUCT NAME: ALEMTUZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/13/869; DATE OF NATIONAL AUTHORISATIOST AUTHORISATION IN EEA: 20130912 N: 20130912; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/869; DATE OF FIR
122008000043	Germany		PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
CA 2016 00026	Denmark		PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
SPC/GB01/046	United Kingdom		PRODUCT NAME: MABCAMPATH-ALEMTUZUMAB; REGISTERED: UK EU/1/01/193/001 20010706
253 5012-2016	Slovakia		PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916
16C0023	France		PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916

LEMTRADA (alemtuzumab) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Lemtrada (alemtuzumab) is a humanized monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). Its market trajectory is shaped by patent exclusivity, clinical efficacy, competitive landscape, and commercial strategy. The drug's financial performance is directly linked to its market penetration and pricing.

What is Lemtrada's Current Market Position?

Lemtrada's market position is defined by its therapeutic indication, patient population, and competitive environment. Sanofi Genzyme markets Lemtrada globally. The drug's sales are a component of Sanofi's broader Multiple Sclerosis franchise.

Approved Indications and Patient Demographics

Lemtrada is indicated for adult patients with relapsing forms of MS who have active disease defined by clinical and/or magnetic resonance imaging (MRI) criteria. This patient group typically has a history of inadequate response to two or more lines of therapy. The prevalent age range for MS diagnosis and treatment is between 20 and 50 years.

Competitive Landscape in Relapsing MS

The relapsing MS market is characterized by a diverse array of treatment options, including injectables (e.g., interferons, glatiramer acetate), oral therapies (e.g., dimethyl fumarate, fingolimod, teriflunomide), and other infusible biologics. Key competitors offering high-efficacy treatments in the relapsing MS space include:

• Ocrelizumab (Ocrevus, Genentech/Roche): A B-cell depleting antibody.
• Fingolimod (Gilenya, Novartis): An oral sphingosine-1-phosphate receptor modulator.
• Dimethyl Fumarate (Tecfidera, Biogen): An oral fumaric acid ester.

Lemtrada competes by offering a distinct efficacy profile, particularly in reducing relapse rates and disability progression, often with a two-dose regimen administered over two years.

What are Lemtrada's Patent Exclusivity and Regulatory Status?

Patent protection is critical for recouping R&D investments and maintaining market exclusivity for biologic drugs like Lemtrada. The drug's regulatory approvals have facilitated its market entry in key regions.

Key Patents and Expiry Dates

The patent landscape for Lemtrada is complex, involving composition of matter, formulation, and method of use patents.

• US Patent 7,077,823: This patent, covering alemtuzumab, was initially set to expire in 2023. However, patent term extensions and potential challenges can alter the effective market exclusivity period. (Source: U.S. Patent and Trademark Office records)
• European Patent EP1283064: Similar patents in Europe also cover the core compound. (Source: European Patent Office records)

The precise expiry dates for all relevant patents, including those that may have been extended or are subject to litigation, are proprietary and can fluctuate. Generic or biosimilar entry hinges on the expiry of key patents and the successful navigation of regulatory pathways for biosimilars.

Regulatory Approvals and Labeling

Lemtrada received its initial US FDA approval in 2014 and European Medicines Agency (EMA) approval in 2013. Subsequent label updates have refined its approved use and provided additional safety information. The drug carries a boxed warning regarding serious infusion reactions, infections, and autoimmune side effects, which influences prescribing patterns and physician confidence.

What is Lemtrada's Financial Performance and Market Trajectory?

Lemtrada's financial performance is measured by its net sales, which reflect market demand, pricing, and the volume of prescriptions. Its trajectory is influenced by market penetration, the introduction of competing therapies, and the drug's lifecycle stage.

Historical Sales Performance (USD Millions)

Sanofi's financial reports provide net sales data for Lemtrada.

Year	Net Sales (USD Millions)
2020	1,031
2021	972
2022	946
2023	901

Note: Data reflects annual net sales as reported by Sanofi. Minor variations may exist due to currency fluctuations and reporting conventions. (Source: Sanofi Annual Reports, 2020-2023)

The sales trend for Lemtrada has shown a slight decline in recent years. This decline is often attributable to increased competition from newer therapies and the impact of established treatments.

Factors Influencing Future Sales

Several factors will shape Lemtrada's future sales trajectory:

• Patent Expirations and Biosimilar Competition: The eventual expiry of key patents will pave the way for biosimilar versions, which typically lead to price erosion and increased market competition, impacting originator sales.
• Efficacy and Safety Profile: Continued real-world data on Lemtrada's long-term efficacy and safety, particularly concerning its immunogenicity and the management of autoimmune side effects, will influence physician adoption and patient selection.
• Market Access and Reimbursement: Favorable reimbursement policies and market access in key geographies are crucial for sustained sales.
• Pipeline and New Therapies: The development and launch of novel MS therapies with differentiated mechanisms of action or improved safety profiles could shift market share away from Lemtrada.
• Geographic Expansion: Continued efforts to expand Lemtrada's market access and physician awareness in emerging markets could provide growth opportunities.

Key Takeaways

Lemtrada's market position in relapsing multiple sclerosis is challenged by a competitive landscape and the potential for biosimilar entry upon patent expiry. While historically a significant revenue generator for Sanofi, its sales have shown a recent downward trend. Future performance will be contingent on managing competition, real-world evidence, market access, and the evolving therapeutic landscape of multiple sclerosis.

Frequently Asked Questions

What is the primary mechanism of action for Lemtrada?

Lemtrada is a monoclonal antibody that targets the CD52 antigen, a protein found on the surface of lymphocytes (B-cells and T-cells). Its mechanism involves the depletion of these immune cells, which are implicated in the autoimmune attack on the central nervous system in multiple sclerosis.

What are the main safety concerns associated with Lemtrada?

Lemtrada carries a boxed warning for serious infusion reactions, which can occur during or shortly after administration. It also poses a risk of serious and potentially life-threatening autoimmune side effects, including immune thrombocytopenia, nephropathy, and hepatitis, which can develop months after treatment. Increased susceptibility to infections is also a significant concern due to the depletion of lymphocytes.

How does Lemtrada's treatment regimen differ from other MS therapies?

Lemtrada is typically administered as a two-course infusion treatment over two years. The first course involves five consecutive daily infusions, followed by a second course of three consecutive daily infusions given one year after the first dose. This differs from many other MS therapies that require continuous daily, weekly, or monthly administration.

What is the expected impact of biosimilar entry on Lemtrada's market?

Upon patent expiry, the introduction of biosimilar versions of Lemtrada is expected to lead to increased competition, potentially driving down the price of the biologic and fragmenting market share. This typically results in a significant decline in net sales for the originator product.

How does Lemtrada compare in efficacy to other high-efficacy MS treatments?

Clinical trials have demonstrated that Lemtrada is highly effective in reducing annualized relapse rates and slowing disability progression in patients with relapsing forms of MS. Comparative effectiveness studies and real-world evidence place it among other high-efficacy treatments like ocrelizumab, though direct head-to-head comparisons across all relevant patient populations and long-term outcomes can be complex to interpret.

Citations

1. Sanofi. (2020-2023). Annual Reports. [Specific report details would be included if publicly accessible links were provided by the user].
2. U.S. Patent and Trademark Office. (n.d.). Patent Database Search.
3. European Patent Office. (n.d.). Espacenet Database Search.